New UK BioPark Opens at Former Roche Products Site
News Apr 03, 2007
BioPark Hertfordshire, the new ‘Outer London’ science park is now open for business, offering established pharma and growing life science companies access to world-class chemistry and biology laboratory facilities.
BioPark Hertfordshire, previously Roche Products pharmaceutical research centre and now owned by the University of Hertfordshire, has 4,500 square metres of chemistry and biology laboratories. The facilities, including fume hoods, safety cabinets, dark rooms, autoclaves and freezer rooms, many of which were upgraded by Roche before they decided to consolidate their UK operations. This means pharmas or life science companies that come to the BioPark can set up their research, without the time or expense of major refurbishment.
With easy-in, easy-out tenancies, a range of laboratory configurations from 30 to 180 square metres linked to write-up areas and offices, the BioPark offers flexible space options. This allows pharma companies with short term projects to use affordable laboratory space for the research’s duration and because each laboratory is accessed via round the clock, guarded entry, project confidentiality is protected.
Located in Welwyn Garden City, the BioPark is ideally situated for national and international travel with good train links to London and Cambridge and three major London airports within an hour’s drive. This makes it a perfect location for international life science companies that want, but do not currently have a UK site.
Bill Sprigings, Marketing Director at BioPark Hertfordshire stated: “We are delighted to take over this excellent suite of facilities from Roche, as it means we can provide competitively priced, yet, much sought after chemistry laboratories and offices in the South of England. This coupled with our flexible letting policy and central location makes BioPark Hertfordshire the right choice for pharmas requiring short term project space or international life science companies looking for an affordable UK base.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.